A number of thiazole derivatives were synthesized according to the Hantzsch thiazole synthesis (1) , along with other methods (2) (3) (4) (5) (6) (7) . Heterocyclic compounds containing thiazole moiety were found to exhibit a wide spectrum of biological activities such as antioxidant (8) , antitubercular (9, 10) , diuretic (11) , antischizophrenia (12) , antibacterial (13, 14) , anti-inflammatory (15) , anti-HIV (16) , antihypertensive (17) , antiallergic (18) , hypnotic (19) , analgesic (20) , antitumor and cytotoxic (21, 22) . Thiazole moiety is present in many drugs such as thiamine (vitamin B 1 ), penicillin (antibiotic), sulfathiazole (antibacterial drug), 2-(4-chlorophenyl)thiazole-4-ylacetic (anti-inflammatory agent), thiabendazole [2-(4-thiazolyl)benzimidazole] (anthelmintic and fungicide), and niridazole [1-(5-nitro-2-thiazolyl)-2-imidazolidinone] (schistosomicidal agent) (23, 24) . Some thiazole derivatives have been recently proven to be anticancer agents (25) . In the present study, we demonstrated the reaction of 4,5,6,7-tetrahydrobenzo[b] thiophene with thioglycolic acid to produce new thiazole derivatives incorporating thiophene moiety and studied their cytotoxicity against different cancer cell lines.
EXPERIMENTAL

General
All melting points were uncorrected and determined on an electrothermal apparatus (Büchi 535, Switzerland) in an open capillary tube. IR spectra (KBr discs) were recorded on a FTIR plus 460 IR spectrophotometer (Shimadzu, Japan). 13 C NMR and 1 H NMR spectra were recorded on a Varian Gemini-200 (200 MHz) (USA) spectrometer in DMSO-d 6 as solvent, using TMS as internal reference and chemical shifts (d, ppm) . Mass spectra were recorded using a Hewlett Packard 5988 (USA) GC/MS system and GCMS-QP 1000 Ex Shimadzu (Japan) using EI (electron impact method). Elemental analyses were carried out on a Vario EL III Elemental CHNS analyzer (Elementar Analysensysteme GmbH, Germany).
Syntheses 2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazol-4(5H)-one (1)
-To a solution of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (1.78 g, 0.01 mol) in acetic acid (30 mL), thioglycolic acid (0.92 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 3 h, then poured into ice/water and the formed solid product was collected by filtration and crystallized from ethanol. (2) . -To compound 1 (2.52 g, 0.01 mol) in dimethylformamide (30 mL), ethyl cyanoacetate (1.13 g, 0.01 mol) was added, then heated in a reflux system for 4 h and poured into an ice/water mixture. The formed solid product was collected by filtration and crystallized from dimethylformamide.
2-Cyano-N-(4,5,6,7-tetrahydro-3-(4,5-dihydro-4-oxothiazol-2-yl)benzo[b]thiophen-2-yl)acetamide
1-(4,5,6,7-Tetrahydro-3-(4,5-dihydro-4-oxothiazol-2-yl)benzo[b]thiophen-2-yl)-3-phenylthiourea (3)
-To the dry solid of compound 1 (2.52 g, 0.01 mol) in 1,4-dioxane (35 mL) containing a catalytic amount of triethylamine (0.50 mL), phenylisothiocyanate (1.35 g, 0.01 mol) was added. The whole reaction mixture was heated under reflux for 4 h, then poured into an acidified ice/water mixture. The formed solid product was collected by filtration and crystallized from 1,4-dioxane. -4,5,6,7-tetrahydrobenzo[b] thiophen-2-yl)-3-phenylthiourea (4) . -To a cold solution (0-5 o C) of compound 3 (3.87 g, 0.01 mol) in ethanol (50 mL) containing sodium hydroxide (0.40 g, 0.01 mol), benzenediazonium chloride (0.01 mol) [prepared by adding a cold solution of sodium nitrite (0.69 g, 0.01 mol) in water (10 mL) to a cold solution (0-5 o C) of aniline (0.93 g, 0.01 mol) in concentrated hydrochloric acid (12 mL) under continuous stirring] was added under continuous stirring. The whole reaction mixture was left at room temperature for 1 h and the solid product formed was collected by filtration and crystallized from ethanol.
1-(3-(5-(2-Phenylhydrazono)-4,5-dihydro-4-oxothiazol-2-yl)
2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-5-bromo-thiazol-4(5H)-one (5) -
To a solution of compound 1 (2.52 g, 0.01 mol) in acetic acid (40 mL) at 50 o C, bromine (1.80 g, 0.01 mol) was added dropwise. The reaction mixture was kept at room temperature for 1 h under continuous stirring. The solid product, when poured into an ice/water mixture, was collected by filtration and recrystallized from acetic acid. [2,3-d] thiazol -5-ol (6b) . General procedure. -To a solution of compound 1 (2.52 g, 0.01 mol) in 1,4-dioxane (40 mL) containing triethylamine (0.50 mL), either malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 5 h, left to cool and then poured into an ice/water mixture containing a few drops of hydrochloric acid. The formed solid product, in each case, was collected by filtration and re-crystallized from 1,4-dioxane. -4,5,6,7-tetrahydrobenzo[b] thiophen-3-yl)-3-phenyl-thiazolo [4,5-d] thiazole-2(3H)-thione (7) . -To a mixture of compound 1 (2.52 g, 0.01 mol) in 1,4-dioxane (35 mL) containing triethylamine (0.50 mL), elemental sulfur (0.32 g, 0.01 mol) and phenylisothiocyanate (1.35 g, 0.01 mol) were added. The reaction mixture was heated under reflux for 5 h and then poured into a beaker containing an acidified ice/water mixture. The solid product was collected by filtration, dried and then recrystallized from 1,4-dioxane. 
2-(2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-7-imino-7H-pyrano[2,3-d]thiazol-5-amine (6a) and 2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-7-imino-7H-pyrano
5-(2-Amino
5-(2-
Phenylhydrazono)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)thiazol-4(5H)-one (8a), (5E)-5-(2-(4-chlorophenyl)hydrazono)-2-(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl) thiazol-4(5H)-one (8b), 5-(2-(4-methoxyphenyl)-hydrazono)-2-(2-amino-4,5,6,7-tetrahydro- benzo[b]thiophen-3-yl)thiazol-4
(5H)-one (8c) and 5-(2-p-tolyl hydra zono) -2-(2-amino-4,5,6,7-tetrahydro ben zo[b]thiophen-3-yl)thiazol-4(5H)-one (8d)
-To a cold solution (0-5 °C) of the diazotized compound 1 [prepared by adding a NaNO 2 (0.69 g, 0.01 mol) solution to a cold solution of 1 (2.52 g, 0.01 mol) in acetic acid (20 mL) and HCl (6 mL, 18 %)], either ethyl cyanoacetate (1.13 g, 0.01 mol) or malononitrile (0.66 g, 0.01 mol) or acetyl acetone (1.00 g, 0.01 mol) or malonic acid diethyl ester (1.60 g, 0.01 mol) in ethanol (20 mL) containing sodium hydroxide (1.00 g) was gradually added under stirring. Upon cooling in an ice-bath, a solid product formed in each case. It was collected by filtration, washed with water and crystallized from ethanol. -4,5,6,7- 
2-(2-Amino
In vitro cytotoxic assay
Fetal bovine serum (FBS) and L-glutamine were purchased from the Gibco Invitrogen Company (UK). RPMI-1640 medium was purchased from Cambrex (USA). Dimethyl sulfoxide (DMSO), CHS-828, penicillin, streptomycin and sulforhodamine B (SRB) were purchased from the Sigma Chemical Company (USA).
No experiments were done on humans. Cancer and normal human cell lines were purchased. Cell cultures were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) while human gastric cancer (NUGC and HR), human colon cancer (DLD-1), human liver cancer (HA22T and HEPG-2), human breast cancer (MCF-7), nasopharyngeal carcinoma (HONE-1) and normal fibroblast cells (WI-38) were kindly provided by the National Cancer Institute (NCI, Cairo, Egypt). Cell lines grew as monolayers and were routinely maintained in RPMI-1640 medium supplemented with 5 % heat inactivated FBS, 2 mmol L -1 glutamine and antibiotics (penicillin 100 U mL
, streptomycin 100 µg mL The prepared heterocyclic compounds were evaluated according to standard protocols for their in vitro cytotoxicity (26) (27) (28) against the six human cancer cell lines: human gastric cancer (NUGC), human colon cancer (DLD-1), human liver cancer (HA22T and HEPG-2), human breast cancer (MCF-7) and nasopharyngeal carcinoma (HONE-1), as well as normal fibroblast cells (WI-38).
The reference compound was (Z)-(6-(4-chlorophenoxy)hexyl)-3-cyano-2-(pyridin-4-yl)guanidine (CHS-828), which is an antitumor agent. The effect of vehicle solvent (DMSO) on the growth of these cell lines was evaluated in all experiments by exposing untreated control cells to the maximum concentration (0.5 %) of DMSO used in each assay.
RESULTS AND DISCUSSION
Chemistry
The reaction of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile with thioglycolic acid gave the thiazole derivative 1. The structure of compound 1 was confirmed on the basis of analytical and spectral data. Thus, the 1 H NMR spectrum showed the presence of multiplets at δ 1.69-1.75 and δ 2.50-2.57 ppm for the four CH 2 groups of Further, compound 1 underwent the Hantzch reaction (1) through its reaction with elemental sulfur and phenylisothiocyanate to give the 3-phenylthiazolo [4,5-d] thiazole derivative 7. The structure of the latter product was based on its analytical and spectral data (see experimental section and Tables I and II) .
Compound 1 showed high reactivity towards diazonium salts; thus, it reacted with any of the diazonium salts, namely, benzenediazonium chloride, 4-chlorobenzenediazonium chloride, 4-methoxybenzenediazonium chloride or 4-methylbenzenediazonium Tables I and II . Cytotoxicity of the newly synthesized products is displayed in Table III . Scheme 2 
Evaluation of in vitro cytotoxic activity
The prepared heterocyclic compounds were tested against six human cancer cell lines, human gastric cancer (NUGC), human colon cancer (DLD-1), human liver cancer (HA22T and HEPG-2), human breast cancer (MCF-7) and nasopharyngeal carcinoma (HONE-1), as well as against normal fibroblast cells (WI-38).
The effects of the newly prepared compounds on six cancer cell lines are presented in Table III . Some heterocyclic compounds exerted marked cytotoxicity against most of the cancer cell lines tested (IC 50 20-100 nmol L ). It was found that some compounds showed cytotoxicity even higher than the reference CHS-828. Thus, compounds 5, 7, 8a, 9b and 10b showed high cytotoxicity towards NUGC, 8a being of comparable activity to the reference drug. Compounds 3, 4, 5, 6b, 8a, 8b, 8d, 9a and 9d showed high cytotoxicity against DLD-1, with the most active 7, 9b and 10b with IC 50 markedly lower than that of CHS-828. The same applies to compounds 6a, 9b and 9c against HA22T. Moreover, compounds 3, 4, 7, 8a, 8b, 8d , 9b, 9d, 10a and 10b showed higher cytotoxicity against HEPG-2 than the reference drug. In the case of HONE-1, 8b could be considered to be of comparable activity to CHS-828, while compounds 10c and 8b showed cytotoxicity comparable to CHS-828 against MCF-7.
Compound 8a was the most active towards the NUGC cancer cell line, compound 10b for DLD-1, compound 6a for HA22T, compound 8b for HEPG-2 and HONE-1 and finally compound 10c for MCF-7, all compared to the standard reference CHS-828. It is important to mention that most of the newly synthesized products showed either no or low cytotoxicity towards the normal cell line WI-38. Scheme 3 
Structure activity relationship
It is clear from the results in Table III that the thiazole moiety was crucial for the cytotoxic effect of cyclic compounds 1-10a-d. Compounds 3, 4, 5, 6a, 7, 8a, 8b, 8d, 9b-d, 10b and 10c exhibited a marked cytotoxic effect against the different cancer cell lines with . The presence of two cyano groups in compound 9b was probably responsible for its higher activity compared to compounds 9a, 9c and 9d. It is obvious that compound 10b showed higher cytotoxicity than 10a, 10c and 10d due to the presence of the Cl group. In conclusion, based on the presented data, the presence of an electron withdrawing group enhanced the potency of the compound. thiophen-2-yl)carbonohydrazonoyl derivative (9b) were most active against all the tested cancer cell lines. Taking into account their non-toxicity towards the normal cell line, compounds 6a, 8a, 8b and 9b might be considered to be of potential therapeutic assistance.
